The future of continuous glucose monitoring: Closed loop

Current Diabetes Reviews

Volumn 4, Issue 3, 2008, Pages 269-279

  Hovorka, Roman ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Artificial pancreas; Automated insulin delivery; Control algorithm; Insulin pump; Model predictive control; PID control; Type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN; INSULIN LISPRO; LONG ACTING DRUG; SHORT ACTING DRUG;

ACCURACY; ALGORITHM; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTINUOUS BLOOD GLUCOSE MONITORING; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN PUMP; INSULIN SENSITIVITY; INSULIN TREATMENT; MATHEMATICAL COMPUTING; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW;

ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; EUROPE; FORECASTING; HUMANS; INCIDENCE; MONITORING, AMBULATORY; NORTH AMERICA; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 54749116015     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339908785294479     Document Type: Review

References (106)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-1053.
2. Diabetes Atlas 2nd edn. International Diabetes Federation, 2003.
3. LaPorte R, Matsushima M, Chang Y. Prevalence and incidence of insulin-dependent diabetes. In NDDG ed. Diabetes in America. 2nd edn. NIH 1995: 37-46.
4. Diabetes Atlas 2nd edn. International Diabetes Federation, 2003.
5. Standards of medical care in diabetes Diabetes Care 2005; 28 (Suppl 1): S4-S36.
6. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25(3): 593-598.
7. Diabetic Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
8. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group Diabetes 1997; 46(2): 271-286.
9. Wentholt IM, Hoekstra JB, Zwart A, DeVries JH. Pendra goes Dutch: lessons for the CE mark in Europe. Diabetologia 2005; 48(6): 1055-1058.
10. Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1978; 1(6107): 204-207.
11. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabetic Med 2006; 23(1): 1-12.
12. Steil GM, Rebrin K. Closed-loop insulin delivery - what lies between where we are and where we are going? Expert Opin Drug Deliv 2005; 2(2): 353-362.
13. Shalitin S, Phillip M. Closing the loop: combining insulin pumps and glucose sensors in children with type 1 diabetes mellitus. Pediatr Diabetes 2006; 7 Suppl 4: 45-49.
14. Renard E, Costalat G, Chevassus H, Bringer J. Artificial beta-cell: clinical experience toward an implantable closed-loop insulin delivery system. Diabetes Metab 2006; 32(5 Pt 2): 497-502.
15. Hovorka R, Wilinska ME, Chassin LJ, Dunger DB. Roadmap to the artificial pancreas. Diabetes Res Clin Pract 2006; 74 Suppl 2: S178-S182.
16. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006; 55(12): 3344-3350.
17. Dassau E, Bequette BW, Palerm CC, et al. Detection of a meal using continuous glucose monitoring (CGM), implications for model predictive control using a real-time CGM. Diabetes 2007; 56 (Suppl 1): A23-A24.
18. Hovorka R, Canonico V, Chassin LJ, et al. Non-linear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas 2004; 25(4): 905-920.
19. Panteleon AE, Loutseiko M, Steil GM, Rebrin K. A novel approach for closed loop control of meal induced carbohydrate uptake. Diabetes Technol Ther 2004; 6(2): 265.
20. Weinzimer SA, Steil GM, Kurtz N, Swan KL, Tamborlane WV. Automated feedback-controlled insulin delivery in children with type 1 diabetes mellitus (T1D): A preliminary report. Diabetes 2006; 55 (Suppl. 1): A102.
21. Renard E, Schaepelynck-Belicar P. Implantable insulin pumps. A position statement about their clinical use. Diabetes Metab 2007; 33(2): 158-166.
22. Gaglia JL, Shapiro AM, Weir GC. Islet transplantation: progress and challenge. Arch Med Res 2005; 36(3): 273-280.
23. Kizilel S, Garfinkel M, Opara E. The bioartificial pancreas: progress and challenges. Diabetes Technol Ther 2005; 7(6): 968-985.
24. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49(8): 1711-1721.
25. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the surgical intensive care unit. N Engl J Med 2001; 345(19): 1359-1367.
26. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354(5): 449-461.
27. Bellomo R, Egi M. Glycemic control in the intensive care unit: why we should wait for NICE-SUGAR. Mayo Clin Proc 2005; 80(12): 1546-1548.
28. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of the critically ill? Diabetologia 2006: 49(8): 1722-5.
29. Muis MJ, Bots ML, Bilo HJ, et al. Determinants of daily insulin use in Type 1 diabetes. J Diabetes Complications 2006; 20(6): 356-360.
30. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care 2007; 30(3): 707-712.
31. Waldhausl W. Circadian rhythms of insulin needs and actions. Diabetes Res Clin Pract 1989; 6(4): S17-S24.
32. Trovati M, Bruno A, Lorenzati R, et al. Preprandial and post-prandial variations of insulin sensitivity in different times of the day assessed by the artificial pancreas in type I diabetics. Chronobiologia 1981; 8(4): 333-340.
33. Bevier WC, Zisser H, Jovanovic L, et al. Effect of pharmacologically induced stress on insulin requirements in subjects with type 1 diabetes mellitus (T1DM). Diabetes 2007; 56: A163.
34. McMahon SK, Ferreira LD, Ratnam N, et al. Glucose requirements to maintain euglycemia after moderate-intensity afternoon exercise in adolescents with type 1 diabetes are increased in a biphasic manner. J Clin Endocrinol Metab 2007; 92(3): 963-968.
35. Wilson DM, Beck RW, Tamborlane WV, et al. The accuracy of the FreeStyle navigator continuous glucose monitoring system in children with type 1 diabetes. Diabetes Care 2007; 30(1): 59-64.
36. Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the CGMS in children with type 1 diabetes: results of the diabetes research in children network (DirecNet) accuracy study. Diabetes Technol Ther 2003; 5(5): 781-789.
37. Mastrototaro J, Soundararajan G, Cooper K, Shah R. Accuracy of real-time continuous glucose monitoring in the MiniMed paradigm system. Diabetes 2007; 56: A112.
38. Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care 2006; 29(12): 2644-2649.
39. Ward WK, Casey HM, Quinn MJ, Federiuk IF, Wood MD. A fully implantable subcutaneous glucose sensor array: enhanced accuracy from multiple sensing units and a median-based algorithm. Diabetes Technol Ther 2003; 5(6): 943-952.
40. Clarke WL, Cox D, Gonder Frederick LA, Carter W, Pohl SL. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care 1987; 10(5): 622-628.
41. Pham M. Healthcare US Equipment and Supplies: Diabetes proprietary survey on insulin pumps and continuous blood glucose monitoring. New York: HSBC Securities (USA) Ltd, 2005.
42. Gin H, Renard E, Melki V, et al. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab 2003; 29(6): 602-607.
43. Belicar PS, Vague P, Lassmann-Vague V. Reproducibility of plasma insulin kinetics during intraperitoneal insulin treatment by programmable pumps. Diabetes Metab 2003; 29(4): 344-348.
44. Selam JL. External and implantable insulin pumps: current place in the treatment of diabetes. Exp Clin Endocr Diab 2001; 109: S333-S340.
45. Thompson JS, Duckworth WC, Saudek CD, Giobbie-Hurder A. Surgical experience with implantable insulin pumps. Department of Veterans Affairs Implantable Insulin Pump Study Group. Am J Surg 1998; 176(6): 622-626.
46. Steil GM, Panteleon AE, Rebrin K. Closed-loop insulin delivery-the path to physiological glucose control. Adv Drug Deliv Rev 2004; 56(2): 125-144.
47. Albisser AM, Leibel BS, Ewart TG, et al. An artificial endocrine pancreas. Diabetes 1974; 23: 389-404.
48. Clemens AH. Feedback control dynamics for glucose controlled insulin infusion system. Med Prog Technol 1979; 6(3): 91-98.
49. Bequette BW. A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. Diabetes Technol Ther 2005; 7(1): 28-47.
50. Parker RS, Doyle FJ, III, Peppas NA. The intravenous route to blood glucose control. IEEE Eng Med Biol Mag 2001; 20(1): 65-73.
51. Shimoda S, Nishida K, Sakakida M, et al. Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas. Front Med Biol Eng 1997; 8(3): 197-211.
52. Parker RS, Doyle FJ, III, Peppas NA. A model-based algorithm for blood glucose control in type I diabetic patients. IEEE Trans Biomed Eng 1999; 46(2): 145-157.
53. Lynch SM, Bequette BW. Estimation-based model predictive control of blood glucose in type I diabetics: A simulation study. Proc of the IEEE 27th Annual Northeast Bioengineering Conference 2001; 79-80.
54. Trajanoski Z, Wach P. Neural predictive controller for insulin delivery using the subcutaneous route. IEEE Trans Biomed Eng 1998; 45(9): 1122-1134.
55. Renard E, Shah R, Miller M, et al. Sustained safety and accuracy of central IV glucose sensors connected to implanted insulin pumps and short-term closed-loop trials in diabetic patients. Diabetes 2003; 52 (Suppl 2): A36.
56. Schaller HC, Schaupp L, Bodenlenz M, et al. Avoidance of hypo- and hyperglycaemia with a control loop system in patients with Type 1 DM under daily life, conditions. Diabetes Metab 2003; 29: A2225.
57. Galley P, Wagner R, Buck H, et al. Use of subcutaneous glucose measurements to drive real-time algorithm-directed insulin infusion recommendations. Diabetes Technol Ther 2004; 6: 245-246.
58. Service FJ, Molnar GD, Rosevear JW, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970; 19(9): 644-655.
59. Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood sugar control in diabetics. Acta Med Scand 1965; 177: 95-102.
60. Wojcicki JM. "J"-index. A new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res 1995; 27(1): 41-42.
61. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006; 29(11): 2433-2438.
62. Chassin LJ, Wilinska ME, Hovorka R. Grading system to assess clinical performance of closed-loop glucose control. Diabetes Technol Ther 2005; 7(1): 72-82.
63. Clemens AH, Chang PH, Myers RW. The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS). Horm Metab Res 1977; Suppl 7: 23-33.
64. Goriya Y, Kawamori R, Shichiri M, Abe H. The development of an artificial beta cell system and its validation in depancreatized dogs: the physiological restoration of blood glucose homeostasis. Med Prog Technol 1979; 6(3): 99-108.
65. Shichiri M, Kawamori R, Yamasaki Y, Hakui N, Abe H. Wearable artificial endocrine pancrease with needle-type glucose sensor. Lancet 1982; 2(8308): 1129-1131.
66. Kawamori R, Shichiri M. Wearable artificial endocrine pancreas with needle-type glucose sensor. In Nose Y. Kjellstrand C, Ivanovich P eds. Progress in Artificial Organs. Cleveland: ISAO Press 1986: 647-52.
67. Shimoda S, Nishida K, Sakakida M, Matsuo Y, Araki E. Development of closed-loop intraperitoneal insulin infusion algorithm for a implantable artificial endocrine pancreas. Diabetes 2001; 50 (Suppl 2): A3.
68. Hashiguchi Y, Sakakida M, Nishida K, et al. Development of a miniaturized glucose monitoring system by combining a needle-type glucose sensor with microdialysis sampling method. Long-term subcutaneous tissue glucose monitoring in ambulatory diabetic patients. Diabetes Care 1994; 17(5): 387-396.
69. Shichiri M. Artificial Endocrine Pancreas: Development and Clinical Applications. Kumamoto: Kamome Press, 2000.
70. Steil GM, Rebrin K, Janowski R, Darwin C, Saad MF. Modeling beta-cell insulin secretion-implications for closed-loop glucose homeostasis. Diabetes Technol Ther 2003; 5(6): 953-964.
71. Panteleon AE, Loutseiko M, Steil GM, Rebrin K. Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system. Diabetes 2006; 55(7): 1995-2000.
72. Steil GM, Loutseiko M, Kurtz N, et al. Tuning closed-loop insulin delivery based on known daily insulin requirements. Diabetes 2002; 51 (Suppl 2): 510.
73. Galley PJ, Thukral A, Chittajallu SK, Weinert S. Diabetes management system. [US Patent 6544212], 1-17. 2003. Ref Type: Patent
74. Schoemaker M, Andreis E, Roper J, et al. The SCGM1 System: subcutaneous continuous glucose monitoring based on microdialysis technique. Diabetes Technol Ther 2003; 5(4): 599-608.
75. Hovorka R, Chassin LJ, Wilinska ME, et al. Closing the loop: The Adicol experience. Diabetes Technol Ther 2004; 6(3): 307-318.
76. Beyer U, Schafer D, Thomas A, et al. Recording of subcutaneous glucose dynamics by a viscometric affinity sensor. Diabetologia 2001; 44(4): 416-423.
77. Vering T. Minimally invasive control loop system for SC-SC control on patients with type 1 diabetes. Diabetes Technol Ther 2004; 6(2): 278.
78. Freckmann G, Kalatz B, Pfeiffer B, Hoss U, Haug C. Recent advances in continuous glucose monitoring. Exp Clin Endocr Diab 2001; 109: S347-S357.
79. Kalatz B, Hoss U, Gessler R, et al. Development of algorithms for feedback-controlled subcutaneous infusion with insulin lispro. Acta Diabetol 1999; 36: 215.
80. Kalatz B. Algorithmen zur Glucosegesteuerten Insulininfusion bei Diabetes Mellitus - Entwicklung und Experimentelle Untersuchung. Ulm: Medical Dissertation, 1999.
81. Renard E, Costalat G, Bringer J. From external to implantable insulin pump, can we close the loop? Diabetes Metab 2002; 28(4): S19-S25.
82. Renard E. Implantable closed-loop glucose-sensing and insulin delivery: the future for insulin pump therapy. Curr Opin Pharmacol 2002; 2(6): 708-716.
83. Renard E, Costalat G, Chevassus H, Bringer J. Closed loop insulin delivery using implanted insulin pumps and sensors in type 1 diabetic patients. Diabetes Res Clin Pract 2006; 74 Suppl 2: S173-S177.
84. Rebrin K, Fischer U, von Woedtke T, Abel P, Brunstein E. Automated feedback control of subcutaneous glucose concentration in diabetic dogs. Diabetologia 1989; 32(8): 573-576.
85. El-Khatib FH, Jiang J, Damiano ER. Adaptive closed-loop control provides blood-glucose regulation using dual subcutaneous insulin and glucagon infusion in diabetic swine. J Diabetes Sci Technol 2007; 1(2): 181-192.
86. Chassin LJ, Wilinska ME, Hovorka R. Evaluation of glucose controllers in virtual environment: Methodology and sample application. Artif Intell Med 2004; 32(3): 171-181.
87. Chassin LJ. In Silico Testing of Glucose Controllers: Methodology and Sample Application (PhD Thesis). London: City University, 2005.
88. Hovorka R, Shojaee-Moradie F, Carroll PV, et al. Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT. Am J Physiol 2002; 282: E992-E1007.
89. Dalla MC, Raimondo DM, Rizza RA, Cobelli C. GIM, simulation software of meal glucose - insulin model. J Diabetes Sci Technol 2007; 1(3): 323-330.
90. Basu R, Dalla Man C, Campioni M, et al. Effects of age and sex on postprandial glucose metabolism: differences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes 2006; 55(7): 2001-2014.
91. Fabietti PG, Canonico V, Orsini-Federici M, Sarti E, Massi-Benedetti M. Clinical validation of a new control-oriented model of insulin and glucose dynamics in subjects with type 1 diabetes. Diabetes Technol Ther 2007; 9(4): 327-338.
92. Berger M, Rodbard D. Computer-simulation of plasma-insulin and glucose dynamics after subcutaneous insulin injection. Diabetes Care 1989; 12: 725-736.
93. Lehmann ED. Preliminary experience with the Internet release of AIDA - an interactive educational diabetes simulator. Comput Methods Programs Biomed 1998; 56(2): 109-132.
94. Roy A, Parker RS. Dynamic modeling of exercise effect on plasma glucose and insulin levels. J Diabetes Sci Technol 2007; 1(3): 338-347.
95. JDRF Artificial Pancreas Project, http://www.jdrf.org/ artificialpancreas (accessed 10 Aug 2007) 2007.
96. Randomized Study of Real-Time Continuous Glucose Monitors in the Management of Type 1 Diabetes, http://clinicaltrials.gov/ct/show/ NCT00406133?order=1 (accessed 10 Aug 2007) 2007.
97. Hovorka R, Wilinska ME, Chassin LJ, Acerini CL, Dunger DB. The artificial pancreas: making headway. Pract Diabetes Int 2007; 24(2): 56-58.
98. http://www.fda.gov/oc/initiatives/criticalpath/reports/opp_list.pdf (assessed 10 Aug 2007) 2006.
99. U.S. Food and Drug Administration. Office of Combination Products, http://www.fda.gov/oc/combination (accessed 21 Aug 2007). 2007.
100. Steiner SS, Hompesch M, Pohl R, et al. Pharmacokinetics and pharmacodynamics of insulin VIAject (TM) and regular human insulin when injected subcutaneously directly before a meal in patients with Type I diabetes. Diabetes 2007; 56 (Suppl 1): A9.
101. Shichiri M, Sakakida M, Nishida K, Shimoda S. Enhanced, simplified glucose sensors: long-term clinical application of wearable artificial endocrine pancreas. Artif Organs 1998; 22(1): 32-42.
102. Schaller HC, Schaupp L, Bodenlenz M, et al. On-line adaptive algorithm with glucose prediction capacity for subcutaneous closed loop control of glucose: evaluation under fasting conditions in patients with Type 1 diabetes. Diabet Med 2006; 23(1): 90-93.
103. Canonico V, Orsini-Federici M, Ferolla P, et al. Evaluation of a feedback model based on simulated interstitial glucose for continuous insulin infusion. Diabetologia 2002; 45 (Suppl 2): 995.
104. Mastrototaro J. The MiniMed Continuous Glucose Monitoring System (CGMS). J Pediatr Endocr Met 1999; 12: 751-758.
105. Renard E, Panteleon AE, Leong P, et al. Efficacy of closed loop control of blood glucose based on an implantable iv sensor and intraperitoneal pump. Diabetes 2004; 53 (Suppl 2): A114.
106. Hoss U, Kalatz B, Gessler R, et al. A novel method for continuous online glucose monitoring in humans: the comparative microdialysis technique. Diabetes Technol Ther 2001; 3(2): 237-243.